Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, Richard Dillon et autres
gb, dk, nz (code pays fourni par la source)